Search Results

ML364 5 mg  | 100.00%

TargetMol

ML364 is an inhibitor of ubiquitin specific peptidase 2 (USP2) and can be used for the research of breast cancer.

More Information Supplier Page

PLX8394 10 mg  | 100.00%

TargetMol

PLX8394 is an orally active inhibitor of serine/threonine-protein kinase B-Raf (BRAF) protein. PLX8394 can selectively bind to and inhibit the activity of both wild-type and mutated forms of BRAF, then inhibit the proliferation of tumor cells which express mutated forms of BRAF. PLX8394 appears to be effective against tumors that express multiple mutated forms of […]

More Information Supplier Page

NIH-12848 5 mg  | 99.84%

TargetMol

NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.

More Information Supplier Page

NIH-12848 50 mg  | 99.84%

TargetMol

NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.

More Information Supplier Page

NIH-12848 25 mg  | 99.84%

TargetMol

NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.

More Information Supplier Page

NIH-12848 10 mg  | 99.84%

TargetMol

NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.

More Information Supplier Page

NIH-12848 100 mg  | 99.84%

TargetMol

NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.

More Information Supplier Page

E4CPG 5 mg  | 99.96%

TargetMol

E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.

More Information Supplier Page

E4CPG 50 mg  | 99.96%

TargetMol

E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.

More Information Supplier Page